Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

por Wuerstlein, R., Kates, R., Gluz, O., Grischke, E. M., Schem, C., Thill, M., Hasmueller, S., Köhler, A., Otremba, B., Griesinger, F., Schindlbeck, C., Trojan, A., Otto, F., Knauer, M., Pusch, R., Harbeck, N.
Publicado 2019

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

por Witzel, I, Loibl, S, von Minckwitz, G, Eidtmann, H, Fehm, T, Khandan, F, Schmatloch, S, Hauschild, M, Bischoff, J, Fasching, P A, Mau, C, Schem, C, Rack, B, Meinhold-Heerlein, I, Liedtke, C, Karn, T, Huober, J, zu Eulenburg, C, Issa-Nummer, Y, Untch, M, Müller, V
Publicado 2012